Search Results 101-110 of 23904 for pharmacogenetics
The Mayo Clinic Center for Individualized Medicine's Bioinformatics Program processes, analyzes and interprets raw genomic sequencing data.
Title: A multi-gene Pharmacogenetic panel to prevent adverse drug reactions in daily primary care practice: an open-label, Mayo Clinic multisite (Mankato ...
Research teams combine multi-omic technologies and data to develop precision diagnostics and therapeutics for patients with various types of cancers, rare ...
Dasburg Professor in Cancer Genomics Research at Mayo Clinic in Rochester. He is a pioneer in pharmacogenetics, and his continuing translational work in ...
Rodriguez-Bravo, studies cell and molecular biology mechanisms of genome organization and stability regulation in cancer. The lab has a special interest in ...
In a prospective, multisite study, 15.2% of patients with pancreatic cancer were found to have a genetic predisposition to this deadly disease.
A second class of drugs that may lead to weight loss and improved blood sugar control is the sodium glucose cotransporter 2 (SGLT-2) inhibitors. These include ...
This medicine is also given to patients with metastatic cancer of the colon or rectum who have received fluorouracil but disease has progressed or recurred.
Albinism. · Birthmarks. · Carney complex. · Cowden syndrome. · Cutaneous mosaicism. · Cutis laxa. · Dyskeratosis congenita. · Ectodermal dysplasia.
Pharmacogenetics in Lung Transplant Patients Jacksonville, FL. The purpose of this study is to: Demonstrate pharmacogenetic variability in the Mayo Clinic ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can go twice as far to fight cancer.